BioVie (BIVI) Competitors $3.05 -0.06 (-1.93%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends BIVI vs. ENLV, TYME, ANRO, DERM, PYXS, COYA, RANI, INMB, VXRT, and QNCXShould you be buying BioVie stock or one of its competitors? The main competitors of BioVie include Enlivex Therapeutics (ENLV), Tyme Technologies (TYME), Alto Neuroscience (ANRO), Journey Medical (DERM), Pyxis Oncology (PYXS), Coya Therapeutics (COYA), Rani Therapeutics (RANI), INmune Bio (INMB), Vaxart (VXRT), and Quince Therapeutics (QNCX). These companies are all part of the "medical" sector. BioVie vs. Enlivex Therapeutics Tyme Technologies Alto Neuroscience Journey Medical Pyxis Oncology Coya Therapeutics Rani Therapeutics INmune Bio Vaxart Quince Therapeutics BioVie (NASDAQ:BIVI) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations. Which has better earnings and valuation, BIVI or ENLV? Enlivex Therapeutics is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioVieN/AN/A-$32.12M-$11.50-0.27Enlivex TherapeuticsN/AN/A-$29.07M-$1.18-0.79 Do analysts recommend BIVI or ENLV? BioVie presently has a consensus price target of $4.00, suggesting a potential upside of 31.15%. Enlivex Therapeutics has a consensus price target of $6.00, suggesting a potential upside of 545.65%. Given Enlivex Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Enlivex Therapeutics is more favorable than BioVie.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioVie 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Enlivex Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Does the media prefer BIVI or ENLV? In the previous week, Enlivex Therapeutics had 1 more articles in the media than BioVie. MarketBeat recorded 2 mentions for Enlivex Therapeutics and 1 mentions for BioVie. Enlivex Therapeutics' average media sentiment score of 1.15 beat BioVie's score of 0.95 indicating that Enlivex Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioVie 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Enlivex Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is BIVI or ENLV more profitable? Enlivex Therapeutics' return on equity of -71.76% beat BioVie's return on equity.Company Net Margins Return on Equity Return on Assets BioVieN/A -182.62% -102.55% Enlivex Therapeutics N/A -71.76%-60.78% Do institutionals and insiders believe in BIVI or ENLV? 4.6% of BioVie shares are held by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are held by institutional investors. 4.0% of BioVie shares are held by company insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community favor BIVI or ENLV? Enlivex Therapeutics received 36 more outperform votes than BioVie when rated by MarketBeat users. Likewise, 79.10% of users gave Enlivex Therapeutics an outperform vote while only 65.38% of users gave BioVie an outperform vote. CompanyUnderperformOutperformBioVieOutperform Votes1765.38% Underperform Votes934.62% Enlivex TherapeuticsOutperform Votes5379.10% Underperform Votes1420.90% Which has more risk and volatility, BIVI or ENLV? BioVie has a beta of 0.4, indicating that its share price is 60% less volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. SummaryEnlivex Therapeutics beats BioVie on 13 of the 16 factors compared between the two stocks. Ad Chaikin Analytics50-year Wall Street legend: “Sell this tech stock NOW”Something very strange is happening to U.S. stocks following President Trump's victory... And this could spell disaster for some of America's favorite tech companies. You can watch for it for free, right here. Get BioVie News Delivered to You Automatically Sign up to receive the latest news and ratings for BIVI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BIVI vs. The Competition Export to ExcelMetricBioViePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$28.46M$7.00B$5.38B$8.84BDividend YieldN/A8.11%5.13%4.09%P/E Ratio-0.2711.01105.0417.81Price / SalesN/A361.871,235.79158.52Price / CashN/A52.5940.3536.29Price / Book2.0210.377.086.50Net Income-$32.12M$153.60M$119.58M$226.22M7 Day Performance-4.39%4.59%2.25%4.03%1 Month Performance18.68%-6.28%-2.34%4.92%1 Year Performance-37.24%33.39%33.95%29.30% BioVie Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BIVIBioVie1.3671 of 5 stars$3.05-1.9%$4.00+31.1%-37.2%$28.46MN/A-0.2710ENLVEnlivex Therapeutics3.2226 of 5 stars$0.88+4.0%$6.00+585.7%-49.2%$18.73MN/A-0.7370Positive NewsTYMETyme TechnologiesN/A$0.31flatN/A+0.0%$53.51MN/A-2.2217Gap DownHigh Trading VolumeANROAlto Neuroscience3.8234 of 5 stars$4.34+6.1%$20.00+360.8%N/A$117.05M$210,000.000.00N/ADERMJourney Medical3.0533 of 5 stars$5.54+6.5%$9.38+69.2%N/A$115.73M$57.77M-5.8490Analyst RevisionPYXSPyxis Oncology1.1598 of 5 stars$1.92-8.6%$10.00+420.8%+35.7%$114.18MN/A-2.0760Analyst ForecastNews CoverageHigh Trading VolumeCOYACoya Therapeutics2.8122 of 5 stars$6.65+9.4%$16.67+150.6%+31.6%$111.12M$6M-9.356Gap UpRANIRani Therapeutics3.1699 of 5 stars$2.07+1.5%$11.71+465.9%+3.5%$110.56M$2.72M-1.92110Analyst ForecastINMBINmune Bio1.7566 of 5 stars$4.91+3.2%$20.00+307.3%-43.6%$108.86M$160,000.00-2.1910VXRTVaxart2.573 of 5 stars$0.61+1.0%$3.00+395.8%-16.8%$107.36M$7.38M-1.46109Analyst RevisionPositive NewsQNCXQuince Therapeutics2.6571 of 5 stars$2.43+16.8%$8.50+249.8%+116.3%$106.92MN/A-1.6860Positive NewsGap Up Related Companies and Tools Related Companies Enlivex Therapeutics Competitors Tyme Technologies Competitors Alto Neuroscience Competitors Journey Medical Competitors Pyxis Oncology Competitors Coya Therapeutics Competitors Rani Therapeutics Competitors INmune Bio Competitors Vaxart Competitors Quince Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BIVI) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioVie Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioVie With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
